{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:03Z","timestamp":1777858143305,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>Clinical observations indicate no cataractogenic potential for quetiapine, in contrast to studies in laboratory animals. This randomized, non-inferiority study compared changes in lens opacity during long-term treatment with quetiapine versus risperidone. Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study. Two ophthalmologists examined each patient 6-monthly for presence of nuclear opalescence (N) and cortical (C) or posterior subcapsular opacification (P), according to the lens opacities classification system II. 1098 patients were randomized to treatment. Mean doses were 386.3 mg\/day quetiapine and 3.2 mg\/day risperidone. Estimated absolute risk differences in cataractogenic events for quetiapine versus risperidone over 2 years were \u22120.035 (C), \u22120.012 (N) and \u22120.017 (P), with upper margins of confidence intervals within the non-inferiority margin of 10%. In post hoc analysis, risk of any lens opacification event was significantly lower for quetiapine than risperidone (6 and 16 events, respectively; risk difference: \u22120.058; P = 0.035). Efficacy and other safety assessments were in agreement with known profiles of these medications. Quetiapine was non-inferior to risperidone for changes in lens opacity grade in patients with schizophrenia or schizoaffective disorder, indicating that quetiapine does not have clinically significant cataractogenic potential during long-term treatment.<\/jats:p>","DOI":"10.1177\/0269881114553253","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:26:01Z","timestamp":1413332761000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial"],"prefix":"10.1177","volume":"29","author":[{"given":"Alan M","family":"Laties","sequence":"first","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan J","family":"Flach","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Baldycheva","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA - former employee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihor","family":"Rak","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA - former employee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willie","family":"Earley","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA - former employee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA - former employee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"bibr1-0269881114553253","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","edition":"4"},{"key":"bibr2-0269881114553253","unstructured":"AstraZeneca Pharmaceuticals (2013) Quetiapine fumarate [summary of product characteristics]. Revised. Available at: http:\/\/www.medicines.org.uk. Accessed 28 March 2014."},{"key":"bibr3-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"bibr4-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090010016003"},{"key":"bibr5-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1989.01070020053028"},{"key":"bibr6-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1097\/00006324-199311000-00011"},{"key":"bibr7-0269881114553253","first-page":"321","volume":"29","author":"Endicott J","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"bibr8-0269881114553253","first-page":"18","volume":"9","author":"Forrest FM","year":"1966","journal-title":"Proc West Pharmacol Soc"},{"key":"bibr9-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.05.038"},{"key":"bibr10-0269881114553253","first-page":"3","volume":"9","author":"Friedman JH","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"bibr11-0269881114553253","first-page":"S119","volume":"73","author":"Garner LL","year":"1974","journal-title":"Wis Med J"},{"key":"bibr12-0269881114553253","first-page":"663","volume":"90","author":"Greiner AC","year":"1964","journal-title":"Can Med Assoc J"},{"key":"bibr13-0269881114553253","doi-asserted-by":"crossref","unstructured":"Guy W (1976) Abnormal involuntary movement scale. ECDEU assessment manual for psychopharmacology, revised edition. US Department of Health, Education, and Welfare: Rockville, MD.","DOI":"10.1037\/e591322011-001"},{"key":"bibr14-0269881114553253","unstructured":"Guy W, Bonato RR (1970) CGI clinical global impression. In: Guy W, Bonato RR (eds), Manual for the ECDEU assessment battery. 2nd ed revised edn. US Department of Health, Education, and Welfare: Chevy Chase, MD, pp 12\u20131\u201312\u20136."},{"key":"bibr15-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"bibr16-0269881114553253","volume-title":"Abstracts of the 39th Annual Meeting of the American College of Neuropsychopharmacology","author":"Laties A","year":"2000"},{"key":"bibr17-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150107018"},{"key":"bibr18-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/26.6.1314"},{"key":"bibr19-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"bibr20-0269881114553253","first-page":"2138","volume":"34","author":"Magno BV","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr21-0269881114553253","first-page":"719","volume":"22","author":"Mantel N","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"bibr22-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90151-3"},{"key":"bibr23-0269881114553253","doi-asserted-by":"publisher","DOI":"10.2165\/11533180-000000000-00000"},{"key":"bibr24-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200011000-00002"},{"key":"bibr25-0269881114553253","first-page":"3","volume":"6","author":"Sartorius N","year":"2007","journal-title":"World Psychiatry"},{"key":"bibr26-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080040005001"},{"key":"bibr27-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.16.2021"},{"key":"bibr28-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.43.5.354"},{"key":"bibr29-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1965.00970040462005"},{"key":"bibr30-0269881114553253","first-page":"10","volume":"29","author":"Siddall JR","year":"1968","journal-title":"Dis Nerv Syst"},{"key":"bibr31-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"bibr32-0269881114553253","doi-asserted-by":"publisher","DOI":"10.3109\/00048679709073828"},{"key":"bibr33-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-44462008000300008"},{"key":"bibr34-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.11.027"},{"key":"bibr35-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)76577-8"},{"key":"bibr36-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2008.tb00154.x"},{"key":"bibr37-0269881114553253","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00161-X"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881114553253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881114553253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881114553253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:17Z","timestamp":1777507697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881114553253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1177\/0269881114553253"],"URL":"https:\/\/doi.org\/10.1177\/0269881114553253","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}